Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 496 entries
View as:

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01160250 Org: User:
Start: 07/31/10 End: 04/30/12 Due: 04/30/13

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal
NCT ID: NCT01366209 Org: User:
Start: 06/30/11 End: 02/28/14 Due: 02/28/15

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

Phase: N/A Priority: Normal
NCT ID: NCT01160861 Org: User:
Start: 07/11/10 End: 04/30/11 Due: 04/30/12

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Phase: N/A Priority: Normal
NCT ID: NCT00476996 Org: User:
Start: 05/15/07 End: 05/14/18 Due: 05/14/19

A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02390492 Org: User:
Start: 03/31/15 End: 04/30/15 Due: 04/30/16

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03289143 Org: User:
Start: 10/04/17 End: 01/15/21 Due: 01/15/22

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase: N/A Priority: Normal
NCT ID: NCT05927571 Org: User:
Start: 08/10/23 End: 07/31/26 Due: 07/31/27

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Phase: N/A Priority: Normal
NCT ID: NCT06137183 Org: User:
Start: 05/01/24 End: 06/16/25 Due: 06/16/26

A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00548548 Org: User:
Start: 09/30/07 End: 11/30/13 Due: 11/30/14

A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT02908100 Org: User:
Start: 01/19/17 End: 07/16/19 Due: 07/16/20

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05462522 Org: User:
Start: 01/16/23 End: 07/08/25 Due: 07/08/26

Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT03237741 Org: User:
Start: 08/07/17 End: 12/14/17 Due: 12/14/18

A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02848651 Org: User:
Start: 09/23/16 End: 05/14/19 Due: 05/14/20

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Phase: N/A Priority: Normal
NCT ID: NCT02608034 Org: User:
Start: 05/26/16 End: 09/10/18 Due: 09/10/19

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Phase: N/A Priority: Normal
NCT ID: NCT04835805 Org: User:
Start: 05/13/21 End: 11/28/25 Due: 11/28/26

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

Phase: N/A Priority: Normal
NCT ID: NCT07025577 Org: User:
Start: 06/30/25 End: 10/15/25 Due: 10/15/26

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

Phase: N/A Priority: Normal
NCT ID: NCT01662063 Org: User:
Start: 08/31/12 End: 06/30/14 Due: 06/30/15

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03747575 Org: User:
Start: 02/06/19 End: 05/05/20 Due: 05/05/21

A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT00962832 Org: User:
Start: 09/30/09 End: 08/31/13 Due: 08/31/14

A Study to Characterize Access to Specialty Care Received by American Indians/Alaska Natives

Phase: N/A Priority: Normal
NCT ID: NCT05624788 Org: User:
Start: 12/02/22 End: 04/15/25 Due: 04/15/26

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02410512 Org: User:
Start: 04/24/15 End: 11/22/19 Due: 11/22/20

A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04468607 Org: User:
Start: 08/31/20 End: 10/16/24 Due: 10/16/25

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Phase: N/A Priority: Normal
NCT ID: NCT01264939 Org: User:
Start: 02/28/11 End: 11/30/12 Due: 11/30/13

A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT06734208 Org: User:
Start: 01/31/25 End: 01/14/27 Due: 01/14/28

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT07008378 Org: User:
Start: 08/01/25 End: 02/01/32 Due: 02/01/33